Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1160790-26-0 | MDL No. : | MFCD11878350 |
Formula : | C13H17BN4O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | BCWMEGZPVCVYPQ-UHFFFAOYSA-N |
M.W : | 272.11 | Pubchem ID : | 49758776 |
Synonyms : |
|
Num. heavy atoms : | 20 |
Num. arom. heavy atoms : | 11 |
Fraction Csp3 : | 0.46 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 5.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 75.63 |
TPSA : | 62.06 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | Yes |
Log Kp (skin permeation) : | -7.06 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 1.27 |
Log Po/w (WLOGP) : | 0.96 |
Log Po/w (MLOGP) : | -0.23 |
Log Po/w (SILICOS-IT) : | 0.29 |
Consensus Log Po/w : | 0.46 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.6 |
Solubility : | 0.68 mg/ml ; 0.0025 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.17 |
Solubility : | 1.83 mg/ml ; 0.00672 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.78 |
Solubility : | 0.0451 mg/ml ; 0.000166 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 3.16 |
Signal Word: | Warning | Class: | |
Precautionary Statements: | P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P330-P363-P501 | UN#: | |
Hazard Statements: | H302-H312-H332 | Packing Group: | |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
33% | Stage #1: 2-(1H-imidazol-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine; 2-(3-ethylureido)benzo[d]thiazol-5-yl trifluoromethanesulfonate With potassium phosphate In water; N,N-dimethyl-formamide for 0.25h; Stage #2: In water; N,N-dimethyl-formamide at 85℃; for 4.25h; | 28 A solution of 2-(3-ethylureido)benzo[d]thiazol-5-yl trifluoromethanesulfonate III (0.075 g, 0.20 mmol), 2-(1 H-imidazol-1 -yl)-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)pyrimidine (0.11 g, 0.40 mmol) and K3PO4 (0.13 g, 0.60 mmol) in DMF-H2O (7.0 mL, 5:2) was degassed by flushing with nitrogen for 15 min. Dichlorobis(triphenylphosphine)-palladium(ll) (0.014 g, 0.020 mmol) was then added to the reaction mixture followed by degassing with nitrogen for another 15 min. The resulting reaction mixture was then heated to 850C for 4 h. After the completion of the reaction (TLC monitoring), the reaction mixture was cooled to room temperature and poured onto ice-cold water followed by extraction with EtOAc (2 x 100 mL). The combined organics was washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The crude was then purified over silica gel (100-200 M, 3.0% MeOH-DCM) to obtain the desired product (0.025 g, 33%). 1H-NMR (400 MHz, DMSO-d6): δ 1.10 (t, J= 7.20 Hz, 3H), 3.19 (m, 2H)1 6.74 (br s, 1 H), 7.18 (s, 1H), 7.68 (dd, J= 1.60 and 8.40 Hz, 1 H), 8.0 (s, 1 H), 8.06 (d, J= 8.40 Hz, 1 H), 8.10 (s, 1H), 8.64 (s, 1 H), 9.27 (s, 2H) and 10.78 (br s, 1 H). MS: 366.12 (M+H)+. Qualitative HPLC Purity (Acquity BEH C-18, 100 x 2.1 mm, 268 nm): 96.87% (Rt = 3.89 min). |
[ 1402240-42-9 ]
2-(4-Methyl-1H-imidazol-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
Similarity: 0.89
[ 1402240-42-9 ]
2-(4-Methyl-1H-imidazol-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
Similarity: 0.89
[ 2304635-68-3 ]
2-(1H-Imidazol-1-yl)-4,6-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
Similarity: 0.85
[ 402960-38-7 ]
5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.81
[ 1402240-42-9 ]
2-(4-Methyl-1H-imidazol-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
Similarity: 0.89
[ 2304635-68-3 ]
2-(1H-Imidazol-1-yl)-4,6-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
Similarity: 0.85
[ 402960-38-7 ]
5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.81
[ 1402240-42-9 ]
2-(4-Methyl-1H-imidazol-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
Similarity: 0.89
[ 1402240-42-9 ]
2-(4-Methyl-1H-imidazol-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
Similarity: 0.89
[ 402960-38-7 ]
5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
Similarity: 0.81